Psychiatric co-morbidity in dystonia-(plus) syndromes: is serotonin the common pathway?

Completed

Conditions: depressieve stemmingsstoornissen en afwijkingen
dystonia (there are no synonyms)
10028037
10002861

Registration Number: NL-OMON40547

Lead Sponsor: niversitair Medisch Centrum Groningen

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Completed

Sex: Not specified

Target Recruitment: 200

Inclusion Criteria

Patients with clinically confirmed diagnosis of idiopathic cervical dystonia (CD) or
Carrier of mutation in DYT11 gene for myoclonus-dystonia (MD) or
Carrier of mutation in GTP-cyclohydrolase 1 gene for dopa-responsive dystonia (DRD)
Only adults ( >= 18 years old) will be eligible for PET-scans

Exclusion Criteria

General exclusion criteria: other neurological conditions past of present, treatment with deep brain stimulation ;Additional exclusion criteria from the PET-scanning:
- SSRI use in the past 6 months to or during the study
- use of medication with a known effect on serotonin receptors or transporters
- pregnancy or nursing
- exhibition to a radiation dose for other reasons, exceeding the maximum annual dose

Study & Design

Study Type: Observational invasive

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The main study parameter is the proportion of dystonia patients having<br /><br>psychiatric co-morbidity, compared to the proportion having psychiatric<br /><br>symptoms in a healthy control population (part A), and the percentage<br /><br>difference in serotonin metabolism (serotonin transporter (SERT) on a [11C]DASB<br /><br>PET scan between subjects with dystonia and healthy controls, and between<br /><br>subjects with and without psychiatric disorders (part B).<br /><br>Serotonin metabolism will be assessed as [11C]-DASB binding potential (BP) as<br /><br>outcome measure for SERT availability in different brain regions of interest<br /><br>(ROIs): brainstem, striatum and frontal cortex. Additionally, a whole brain<br /><br>voxelwise comparison will be performed using Statistical Parametric Mapping<br /><br>(SPM).</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Motor assessment:<br /><br>Severity of dystonia, severity of myoclonic symptoms, clinical severity<br /><br><br /><br>Psychiatric assessment<br /><br>Adults: the presence of Diagnostic and Statistical Manual of Mental Disorders,<br /><br>Fourth Edition (DSM-VI) diagnosis, Life-time prevalence of any psychiatric<br /><br>diagnosis, severity of anxiety symptoms, severity of panic symptoms, severity<br /><br>of social anxiety symptoms and avoidance, severity of OCD symptoms, severity of<br /><br>depressive symptoms<br /><br>Children: the presence of Diagnostic and Statistical Manual of Mental<br /><br>Disorders, Fourth Edition (DSM-VI) diagnosis<br /><br><br /><br>Concentrations of serotonin in platelets<br /><br><br /><br>Genetics: the presence of polymorphisms of 5-HTTLPR<br /><br>(serotonin-transporter-linked polymorphic region), DNA methylation rate of the<br /><br>serotonin transporter gene</p><br>